1.Quan T, Fisher GJ. Role of age-associated alterations of the dermal extracellular matrixmicroenvironment in human aging: a mini-review. Gerontology. 2015;61(5):427-434. 2. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24): 4195-4200. 3. Ganceviciene R, Liakou AI, Theodoridis A, et al. Skin anti-aging strategies. Dermato-Endocrinol. 2012;4(3):308-319. 4. Data on file, Merz North America, Inc., Raleigh, N.C. 5. 5. Gold MH, Katz BE, Cohen JL, Biron J. Human growth factor cream and hyaluronic acid serum in conjunction with micro laser peel: an efficient regimen for skin rejuvenation. J Clin Aesthet Dermatol. 2010;3(12):37-42.
1. Kerscher M, et al. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A. J Drugs Dermatol. 2019; 18(1): 52-7.
2. Frevert J. Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and XEOMIN®/Bocouture®. Drugs R D. 2010;10(2):1-7,67-73.
3. Torres S, et al. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11-7.
4. Stengel G, Bee EK. Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. Clin Interv Aging. 2011;6:281-4.
5. Prager W. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol. 2013;5:39-52.
XEOMIN COSMETIC – please speak to your Healthcare Practitioner.
References: 1. XEOMIN COSMETIC® product monograph, June 2019, 2. Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind
phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg. 2013;39(6):891-899., 3. Kane MA, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1310-1319., 4. Data on file, Merz North America, 2017, 5. Kane M, Sattler G. Illustrated Guide to Botulinum Toxin Injections. Quintessence Publishing Co Ltd 2013:5, 6. Realself.com, February 11, 2019, 7. Thistle F. Greenhouse gas emissions and botulinum neurotoxin packaging. Hospital Pharmacy Europe. 2012; 64:27-30 References: 8. Frevert J. Drugs R D. 2015:15; 1-9.
The BELOTERO range of Hyaluronic Acid fillers are injectable resorbable implants indicated to increase the volume of skin tissue for the correction of facial depressions, or remodeling the contours of the face. After injection, patients may experience redness, bruising, swelling or other local side effects. Most side effects of treatment resolve within a few days. As with any injection there may be risk of infection. Be sure to inform your Healthcare Provider of any known allergies, esp. to sodium hyaluronate and lidocaine hydrochloride (for Lidocaine versions) or to amide-type local anesthetics before treatment.
Please see Instructions for Use for full list of warnings and precautions.
Copyright © 2019 Merz Pharma Canada Ltd. All rights reserved. BELOTERO® and Belotero® are registered trademarks of Merz Pharma GmbH & Co. KGaA.
1. Micheels P et al. Superficial Dermal Injection of Hyaluronic Acid Soft Tissue Fillers: Comparative Ultrasound Study. Dermatol Surg 2012;38:1162–1169.
2. Tran C, et al. In vivo bio-integration of three Hyaluronic Acid fillers in human skin: a histological study. Dermatol. 2014; 228(1):47-54.
3. Prager et al. A prospective, split‐face, randomized, comparative study of safety and 12‐month longevity of three formulations of Hyaluronic Acid dermal filler for treatment of nasolabial
folds NLF, Dermatol Surg. 2012; 38: 1143-1150
4. Fakhari A et al. Applications and Emerging Trends of Hyaluronic Acid in Tissue Engineering, as a Dermal Filler, and in Osteoarthritis Treatment, Acta Biomater. 2013 July; 9(7): 7081-7092
5. Buntrock H et al, Efficacy, safety, and patient satisfaction of a monophasic cohesive polydensified matrix versus a biphasic non-animal stabilized Hyaluronic Acid filler after single
injection in nasolabial folds. Dermatol Surg. 2013;39:1097–1105
6. Belotero Lips Shape, Instructions for Use, 2018
7. Belotero Lips Contour, Instructions for Use, 2018
8 Dhaliwal J, Friedman O. Injectables and fillers in male patients. Facial Plast Surg Clin North Am. 2008 Aug;16(3): 345–355
9. Belotero Soft Lidocaine, Instructions for Use, 2018
10. Belotero Balance Lidocaine, Instructions for Use, 2018
11. Belotero Intense Lidocaine, Instructions for Use, 2018
12. Belotero Volume Lidocaine, Instructions for Use, 2018
RADIESSE is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. After injection, patients may experience redness, bruising, swelling or other local side effects. Most side effects of treatment resolve within a few days. More rare side effects may include swelling that lasts longer, unevenness or firmness in the area injected, and as with any injection, there may be a risk of infection. Be sure to inform your Healthcare Provider of any known allergies, esp. to sodium hyaluronate and lidocaine hydrochloride (for Lidocaine versions) or to amide-type local anesthetics before treatment. Please see Instructions for Use for full list of warnings and precautions. This product may not be right for you. Talk to your Aesthetic Healthcare Professional.
References: 1: Berlin AL, Hussain M, Goldberg DJ. Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immuno-histochemical analysis. Dermatol Surg 2008; 34 (Suppl 1): S64–7. 2: Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: longterm safety and efficacy results. Aesthet Surg J 2010; 30: 235–8. 3: Moers-Carpi MM, Opi Tufet J. Calcium Hydroxylapatite (RADIESSE®) versus Nonanimal Stabilized Hyaluronic Acid (Restylane®) for the Correction of Nasolabial Folds: a 60 patient, 12-Month, Multicenter, Prospective, Randomized, Controlled, Split-Face Trial. Dermatol Surg 2008;34: 210-215. 4: Moers-Carpi M, Vogt S, Martinez Santos B, Planas J, Rovira Vallves S, and Howell DJ. A Multicenter, Randomized Trial Comparing Calcium Hydroxylapatite (RADIESSE®) to Two Hyaluronic Acids (Juvéderm® and Perlane®) for Treatment of Nasolabial Folds. 205 Patients. Dermatol Surg, 2007; 33: S144-S151. 5: Data on File. 6: Sundaram H, Voigts B, Beer K, Meland M, Comparison of the Rheological Properties of Viscosity and Elasticity in Two Categories of Soft Tissue Fillers: Calcium Hydroxylapatite and Hyaluronic Acid, Dermatol Surg 2010, 36 (s3), 1859-1865 7: Dallara, JM. Baspeyras, M. Rui, P. Cartier, H. Charavel, MH. Dumas, L. Calcium Hydroxylapatite for jawline rejuvenation: consensus recommendations. J Cosmet Dermatol 2014: 13: 3-14. 8: Busso, M. Moers-Carpi, M. Storck, R. Ogilvie, P. and Ogilvie, A. Multicenter, Randomized Trial Assessing the Effectiveness and Safety of Calcium Hydroxylapatite for Hand Rejuvenation. Dermatol Surg 2010;36:790–797 9: Dhaliwal J, Friedman O. Injectables and fillers in male patients. Facial Plast Surg Clin North Am. 2008 Aug;16(3): 345–355 10: Marmur, ES, Phelps, R and Goldberg, DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. Journal of Cosmetic Laser Therapy 2004; 6:223-226. 11: Yutskovskaya Y, et al. A Randomized, Split-Face, Histomorphologic Study Comparing a Volumetric Calcium Hydroxylapatite and a Hyaluronic Acid-Based Dermal Filler. J Drugs Dermatol. 2014; 13(9): 47-52 12: Radiesse IFU, March 2017 13: Van Loghem JV, et al. J Clin Aesthetic Dermatol. 2015:8(1)38-49. 14: Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
The non-invasive Ultherapy® procedure is Health Canada Licensed to lift skin on the neck, on the eyebrow and under the chin as well as to reduce the appearance of fine lines and wrinkles on the neck and décolletage. The most common side effects reported in clinical trials were redness, swelling, pain, and bruising. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product and safety information, including a full list of these events.
1. Ulthera Instructions For Use.
2. White WM, Makin IRS, Barthe PG, et al. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy. Arch Facial Plast Surg. 2007;9(1):22-29.
3. Data on File, ULT-132.
4. Laubach HJ, Makin IR, Barthe PG, et al. Intense focused ultrasound: evaluation of a new treatment modality for precise microcoagulation within the skin. Dermatol Surg. 2008;34(5):727-734.
5. Data on File, ULT-300.
6. Dobke MK, Hitchcock T, Misell L, Sasaki OH. Tissue Restructuring by Energy-Based Surgical Tools, Clin Plastic Surg. 2012:39:399-408.
7. Rittie L, Fisher GJ. Natural and sun-induced aging of human skin. Cold Spring Harb Perspect Med. 2015;5(1):a015370.
8. MacGregor JL, Tanzi EL. Microfocused ultrasound for skin tightening. Semin Cutan Med Surg. 2013;32:18-25.
Fabi SG, Goldman MP, Dayan SH, et al. A prospective multicenter pilot study of the safety and efficacy of microfocused ultrasound with visualization for improving lines and wrinkles of the décolleté. Dermatol Surg. 2015;41(3):327-335. SH, et al.
9: realself.com/ultherapy; Jan 13, 2019
10. Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
Baumann L, Zelickson B. Evaluation of Micro-Focused Ultrasound for Lifting and Tightening Neck Laxity. J Drugs Dermatol. 2016;15(5):607-614.
Copyright© 2022 Merz Pharma Canada Ltd. All rights reserved. ULTHERAPY®, NEOCUTIS®, RADIESSE®, XEOMIN COSMETIC® and BELOTERO® are registered trademarks of their respective owners.